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:ةصلاخلا 
فذهلا :  (لا ةٛساسد ةساسذنChromogranin A صٛخشج ٙف ) عًنا  عي ّغاثجسأ ىسجنا ٙف ةفهحخي عقإي ٍي ةٛثصعنا ىصنا دذغنا واسٔاا شٛٚ
.فصنأ وسٕنا عقٕي مثي ةٚشٚشسنأ ةٛظشًنا 
: ةيجهنملا ثقثغ ةساسذنا ِزْ  ةٛثصعنا ىصنا دذغنا واسٔأت  باصي طٚشي ٍٛسًخ ٗهع  ةٛهك ،ضاشيلأا ىهع ىسق ٙف، ةطنا  ٍي ةفٕكنا ةعياج
 َٙاثنا ٌَٕاك3102 ٗنا  لٔلأا ٍٚششج3102 ٍٛت اي حٔاشحج ىْساًعأ ..33-01  ةُس٘شًعنا لذعًنا ٌاكٔ 30.2. ةقٚشغ ثيذخحسا Two step 
Envision 
TM
 flex  ٙعاًُنا شٛثعحنا ذٚذذحن ن ذعحسًki67 (MIB-1)  ٔChromogranin A. 
 : جئاتنلا  ٌاك ةٛثصعنا ىصنا دذغنا واسٔأ ٍي ٌَٕاعٚ ٍٚزنا ٗظشًهن ٙسٛئشنا عقًٕنا ٍٛغشخًُنا ةساسذنا ِزْ ٙف جنا ْٕٓ ٕ٘عًنا ًٙعٓنا صا
طاٚشكُثنأ ثَاكٔ  ،خاَلإا ةًُْٛ كاُْ من ٙعاًُنا شٛثعحنا ٌاك Chromogranin A ْٕ33 (00 )% شٛثعحنا ٍٛت ٖضغي تار ةقلاع ذجٕجلأ
ٙعاًُنا  من A Chromogranin واسٔلأن فصنأ عقًٕنا عي. 
جاتنتسلااتا :Chromogranin A   صٛخشج ٙف ةٚاغهن طاسد ىهعيواسٔأ .فصنأ عقًٕنا ٍع شظُنا فشصت ةٛثصعنا ىصنا دذغنا 
: تايصىتلا خصَُ ت واذخحسا ٙعاًُنا ىهعًناA Chromogranin  ٙسٛئس ىهعًك  واسٔلأا صٛخشج ٙف   ىصنا دذغناةٛثصعنا ةفاظلإات  ٗناةَٛاكيإ 
ّياذخحسا   جلاع ٙف ذٚذج ػًُن فذٓكواسٔلأا . 
 
Abstract :  
objectives: To study the sensitivity of Chromogranin A  in the diagnosis of neuroendocrine tumors from various 
locations in the body and  its association with clinicopathological parameters like site and grade of tumors .  
methodology: This study is conducted in the Department of Pathology, Faculty of Medicine, University of Kufa 
from January - October  2013. 
A total of 50 patients with neuroendocrine tumors from different locations. their ages ranging between 22-80 
years with a mean age of 48.3 years. Two step Envision 
TM
 flex method was employed for immunohistochemical 
detection of ki67 antigen (MIB -1) and Chromogranin A . 
Results: Main site for patients with neuroendocrine tumors included in this study is gastroenteropancreatic 
system and there is female predominance , from 50 patients 44 (88%)  cases was positive for Chromoranin A  
expression , there was no significant differences in expression of the Chromogranin A  with location   and grade 
of tumors (P value >0.05) 
Conclusion: Chromogranin A is highly sensitive marker in diagnosis of neuroendocrine tumors irrespective to 
tumors location and tumor grade . 
Recommendation: We advise to use Chromogranin A immunohistochemical marker as a main  marker in 
diagnosis of neuroendocrie tumors in addition to that this marker can be used as target for new modality in tumor 
therapy .  
Keywords: neuroendocrine tumor ,chromogranin A, ki 67 
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INTRODUCTION  :  
Neuroendocrine tumors (NETs) are relatively rare  that arises from the cell of the 
diffuse neuroendocrine system that scattered in all organs mainly gastrointestinal tract , 
bronchopulmonary system  and others . The annual incidence is approximately 2.5-5 per 
100,000. The prevalence has been estimated as 35 per 100,000, and may be considerably 
higher if clinically silent tumors are included. 
(1) 
 
Most NETs have the ability to  produce and secrete a variety of peptide hormones and 
amines which cause clinical syndromes and are used as markers for the diagnosis of NETs .  
The diagnosis of neuroendocrine tumor patients  with  absence of any symptoms depend on 
detection general NET markers, including the secretory granule proteins (chromogranins A), 
the synaptic vesicle membrane glycoprotein synaptophysin) and the cytosolic  marker (neuron 
specific-enolase ).
(2)
  
Without correct diagnosis the tumor can be falsely diagnosed as adenocarcinoma,  with 
a negative impact patient regarding management and underestimation of prospects for 
survival.
(3)
  there are many classification system for neuroendocrine tumors but the newest 
one was in 2010 which separates neuroendocrine tumors into two main groups:  well-
differentiated NET (grade 1, grade 2) and poorly differentiated NET (G3) neuroendocrine 
carcinoma (NEC), including large cell and small cell neuroendocrine carcinoma (LCNEC and 
SCNEC) that quietly differ in their biological behavior and lines of therapy. 
(4)
  
OBJECTIVES :  
To study the sensitivity of Chromogranin A  in the diagnosis of neuroendocrine tumors from 
various locations in the body and  its association with clinicopathological parameters like site 
and grade of tumors .   
METHODOLOGY :  
This study is conducted in the Department of Pathology, Faculty of Medicine, 
University of Kufa from January - October  2013.A total of fifty  formalin-fixed paraffin-
embedded tissues sections of various organs from histopathologicaly confirm  neuroendocrine 
tumors Iraqi patients were included Thirty five cases from gasteroenteropancreatic system, 9 
cases  from bronchopulmonary  system , 6 cases from other sites, were retrieved from the lab 
unite of al-Sader medical city   in Al Najaf and some of private labs in al-Najaf and Baghdad  
provinces. 
From each tissue block, 3 sections of 4 µm thickness were taken. One section was 
stained with hematoxylin and eosin ,for revision of the histopathological diagnosis, and 
the other 2 sections were stained immunohistochemically using two step Envision 
TM
 
flex  method for Ki-67 Antigen (monoclonal mouse antihuman ki67 antigen, clone MIB-1 , 
Dako Denmark , was used at dilution 1:75.it is nuclear marker) and Chromogranin A 
(monoclonal mouse antihuman Chromogranin , Dako Denmark, used at dilution of 1:400, it is 
cytoplasmic markers). 
With each run of immunostaining  positive  and negative control sections were 
processed, Positive control pancreatic tissues  sections which are known to express 
chromogranin A and small intestine for ki67, while Negative controls   were obtained by 
omitting the primary antibody for the used markers. 
The criterion for positive immunoreaction is dark brown precipitate (cytoplasmic for 
Chromogranin A , and nuclear for Ki 67). While the intensity of chromogranin A staining was 
assessed by counting the percentage of positive cells in 100 malignant cells at objective 40 
total magnification. The immunostaining was calculated as the percentage of immunoreactive 
cells per total number of malignant cells. Each sample was scanned for at least five fields with 
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a high power magnification, chromogranin A assessed as positive or negative (Positive 
staining for chromogranin A should be considerd if >10% of tumor cells was positive ).
(5)
 
 
Table (1) : ki7 scoring system:  
 
Grade  Staining pattern 
Grade I       ≤2% of tumor cells are positive  
Grade II     3%–20% of tumor cells are positive  
Grade III   < 20% of tumor cells  are positive 
 
Table (1) show ki67 scoring system was assessed as percentage of  immunostained cell 
in a total 2,000 tumor cells in areas of highest nuclear labeling (hot spot)at  magnification 40 
x. A low Ki-67 index was defined as ≤2% positive cells, an intermediate index as( 3–
20%)positive cells and a high proliferation index as < 20% positive cells according to recent 
guidelines from World Health Organization (WHO) and  the European Neuroendocrine 
Tumor Society (ENET) recommendations.
(6)
  
 
RESULTS : 
The age of patients included in this study ranged from 22-80 years with a mean age of( 
48.3±13.8 ) years (mean± SD) and peak age group being 41-50 years (26%). (Figure 1). 
Consisting of  females  28 (56%)  outnumber the males 22 (44%).(Figure 2) 
 
 
 
Figure (1): Age distribution of the presented neuroendocrine tumor patients 
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Figure(2): Gender distribution among presented neuroendocrine tumor patients. 
 
 
 
Table (2) :Location of tumor in the presented neuroendocrine tumors  patients 
 
Location of tumors  No. patient Percentage 
Gasteroenteropancreatic system 35 70% 
Bronchopulmonary system 9 18% 
others 6 12% 
Total  50 100% 
 
 Table (2) show Site distribution revealed that  (35) (70%) cases are taken from 
Gastroenteropancreatic (GEP) system, (9) (18%) cases  from  Bronchopulmonary  system, (6) 
(12%) cases from  other sites. 
 
Table(3) : Distribution of tumors within Gastroenteropancreatic system 
 
Site  No. patient Percentage  
Stomach  12 34% 
Pancreas 11 31% 
Small intestine  9 26% 
Colon 1 3% 
Rectum 2 6% 
Total 35 100% 
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Table (3) explain the assessement of site distribution within Gastroeneropancreatic 
neuroendocrine tumors ,the result  revealed that (12 out of 35 )(34%) cases are from stomach, 
(11 out of 35 )(31%) from pancreas, (9 out of 35)(26%) from small intestine, (1 out of 35) 
(3%) from colon and (2 out of 35)(6%) from rectum. 
 
 Table (4): Distribution of   GEP –NET patients according to the grade. 
 
Grade of tumors  No. of patients  Percentage  
Grade I (Ki 67≤2) 9 26% 
Grade II (Ki 67 3-20) 15 43% 
Grade III (Ki67 >20 ) 11 31% 
Total  35 100% 
 
 Table (4) show Grading of Gasteroenteropancreatic neuroendocrine tumors ( GEP-
NET)  were assessed according to the WHO grading system 2010, revealing that grade I was 
reported in (9 )( 26%) of cases, grade II in ( 15) ( 43%), while those of grade III  were (11 ) 
(31 %) cases.   
 
 Table (5): Immunohistochemical expression of Chromogranin A in presented 
neuroendocrine tumor patients.(negative result include both score 0 and +1) 
 
Type of tissue Immunostaining of 
chromogranin A 
Total P 
value 
Positive Negative 
GEP –NET 32(91.43%) 3(8.57%) 35(70%) 0.820 
Bronchopulmonary 
system 
7(77.78%) 2(22.22%) 9(18%) 
Others 5(83.33)% 1(16.67%) 6(12%) 
Total 44(88%) 6(12%) 50(100%)  
 
Table (5) show that Chromogranin A expression   reported in (44 out of 50 cases) (88%) 
and only (6 out of 50 cases )(12%) was negative for Chromogranin A. assessment of 
Chromogranin A expression in neuroendocrine tumors from different location revealed that: 
Gastroenteropancreatic neuroendocrine tumors (32 out of 35cases)(91%)was positive for 
Chromogranin A, only (3 out of 35 cases)(8,57%)was negative, Bronchopulmonary 
neuroendocrine tumors (7 out of 9 cases) (77%78%) was positive and (2 out of 9 
cases)(22,22%) was negative , in other sites only (1 out of 6 cases ) (16.67%) was negative 
while the remaining  5 cases was positive with (83.33%). There was no significant differences 
in expression of chromogranin A among different neuroendocrine tumors in various 
locations.(p>0.05)  ( Figures 3,4 ) 
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Figure (3): Neuroendocrine tumor, showing strong cytoplasmic staining of 
chromogranin A . with presence of intact mucin secreting glandular structure in case of 
intestinal neuroendocrine tumor .[40X] 
 
 
 
 
 
 
Figure (4): Neuroendocrine tumor with trabecular pattern of growth with strong 
staining for chromogranin A .  and  negative staining of nucleus [40X]   
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Figure 5: Neuroendocrine tumors, showing grade III neuroendocrine tumors with 
>20%of tumor cells positive nuclear stain for ki67 [10X]  
 
 
 
Table(6) :  Immunostaining of Chromogranin A in relation to grade of tumor.(negative 
result include both score 0 and +1) 
Grade Immunostaining Chromogranin A Total  
P value Positive Negative 
Grade I 8(88.89%) 1(11.11%) 9(25.71%) 0.609 
Grade II 15(100%) 0 15(42.86%) 
Grade III 9(81.82%) 2(18.18%) 11(31.43%) 
Total 32(91.43%) 3(8.57%) 35(100%)  
 
Table (6) demonastrae that Immunohistochemical analysis of  the Chromogranin A 
protein expression in relation to grade of tumor revealed that positive result of  Chromogranin  
A was reported in (8 out of 9 cases )  of  grade I ,all of cases in grade II was positive for 
Chromogranin A (15 out of 15) ,  ( 9 out of 11) of grade III . There was no significant 
differences between Chromogranin A expression  and grade of tumors.(p>0.05)  
 
DISCUSSION:  
Neuroendocrine tumors relatively rare tumors but with continues increase in the 
incidence  that seem to be  exceed  that of breast and lung , especially this changes occurred 
on basis of tumors location with increase in primary tumors of stomach ,rectum and small 
intestine . 
(7)
 This point bring the attention  to study this tumors from different point of view. 
Immunohistochemical detection of general neuroendocrine marker (chromogranin A, 
synaptophysin, neuron specific enolase ) is considered as most important diagnostic tool for 
neuroendocrine tumors ,so in this study, we investigated the immunohistochemical detection 
rate of chromogranin A ( large secretary granule associated marker)to determine its diagnostic 
sensitivity and its relation to grade and location of tumors. Clinicopathological assessment 
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revealed that gender distribution show that male cases were 24 (48%) & female cases were 26 
(52%) and male to female ratio in the current study was (0.78:1) , this matching with other 
study .
(1) 
and close to .
(8)
 with (58%) female and (42%) male. In the current study patients age 
ranges from (22-80) years with a mean of 48.38, which is  seem to be  similar to other studies. 
(9) (10)
 
Site distribution (70%) of cases were taking from Gastroenteropancreatic (GEP) system, 
(18%) were taking from Bronchopulmonary system &  (12%) from other sites, this pattern of 
site distributiongoing with previous studies.
(7) (11)
  
Within gastroenteropancreatic neuroendocrine tumors the stomach was the main site       
with  (34%) this look to be similar with previous studies.
(12) (8)
 
Regarding grade distribution within Gastroenteropancreatic system Most of cases  in  
   the current study located within Grade II group  (15 out of 35) (43%) in reverse with 
other studies  most of cases located within Grade I group .
(13) (14)
 This  variation in grade 
distribution within GEP-NET may be due to  different grading system that used in the studies. 
Immunohistochemical expression of Chromogranin A have clarified that (44 out of 50 cases) 
(88%) of neuroendocrine tumors were expressing Chromogranin A in their histological 
sections These results have been reported by many investigators over the world. In agreement 
with many other studies reported .
(15)
 
(8)
. 
In neuroendocrine tumors from different locations  , it has been that  chromogranin A  
was positive in (91.4%) of gastroenteropancreatic NET, 77,8% of bronchopulmonary  NET 
and 83.3% of others sites ,without significant difference in chromogranin A expression 
between different  sites (p value  >0.05) these result are corresponding to other study.
(16)
 that 
concern with immunohistochemical detection of chromogranin A specifically in  
neuroendocrine  carcinoma (grade III) . 
The immunohistochemical analysis  of the  Chromogranin A  in relation to grade show 
that immunoexpressionwas noticed in (88.9%) of grade I Gastroenteropancreatic 
neuroendocrine tumors , and in  ( 100%) of  grade II group  Of Gastro entero pancreatic 
neuroendocrine tumors . In grade III, 81.8% of them revealed positive within grade of  tumor .  
Despite there  is higher percent  with  lower grade but There was no significant difference 
among these grades  (P value <0.05 ). This is also supported by literature.
(8) (17)
  
 
CONCLUSION:  
From above result we conclude that chromogranin A is highly sensitive marker in 
diagnosis of neuroendocrine tumors  irrespective to tumor grade and location. 
RECOMMENDATION: 
We advise to use Chromogranin A immunohistochemical marker as a main  marker in 
diagnosis of neuroendocrine tumors in addition to that his marker can be used as target for 
new modality in tumor therapy .  
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